title: Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
abstract: A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis. Patients (n=280) were treated for 12 weeks with candesartan cilexetil 2, 4, or 8 mg given orally once-daily (o.d.). The improvement in urinary protein excretion observed at the end of the treatment period was 15.9% in the 2 mg group, 25.6% in the 4 mg group, and 34.6% in the 8 mg group, respectively, showing a clear dose-response (2 mg <4 mg <8 mg; p=0.003). The mean reduction in urinary protein excretion was 11.3% in the 2 mg group, 26.3% in the 4 mg group, and 26.0% in the 8 mg group, showing a dose-response pattern, in that the effect of 4 mg and 8 mg was greater than that of 2 mg (2 mg <4 mg asymptotically equal to 8 mg; p=0.010). As the observed reduction in urinary protein excretion failed to correlate with changes in mean blood pressure, it could not be attributed to the antihypertensive effect of the study drug alone. This suggests that candesartan cilexetil, 4 8 mg o.d., has antiproteinuric effects in patients with chronic glomerulonephritis.
authors.affiliation: Department of Internal Medicine VII, School of Medicine, Tokai University, Isehara, Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kurokawa
authors.forename: Keishi
authors.initials: K
authors.lastname: Abe
authors.forename: Takao
authors.initials: T
authors.lastname: Saruta
authors.forename: Masaaki
authors.initials: M
authors.lastname: Arakawa
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Kikkawa
authors.forename: Naohiko
authors.initials: N
authors.lastname: Ueda
authors.forename: Kaoru
authors.initials: K
authors.lastname: Onoyama
authors.forename: Kimio
authors.initials: K
authors.lastname: Tomita
authors.forename: Nobuya
authors.initials: N
authors.lastname: Ogawa
mesh_terms: D000328:Adult; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005921:Glomerulonephritis / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology / Q000652:urine; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D003404:Creatinine; C077793:candesartan cilexetil